Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥2,018 JPY
Change Today +39.00 / 1.97%
Volume 1.9M
As of 2:00 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

kyowa hakko kirin co ltd (4151) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/31/15 - ¥2,035
52 Week Low
01/7/15 - ¥1,094
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KYOWA HAKKO KIRIN CO LTD (4151)

Related News

No related news articles were found.

kyowa hakko kirin co ltd (4151) Related Businessweek News

No Related Businessweek News Found

kyowa hakko kirin co ltd (4151) Details

Kyowa Hakko Kirin Co., Ltd., a research-based life sciences company, manufactures and markets pharmaceuticals and bio-chemicals in Japan and other Asian countries, Europe, the United States, and internationally. The company’s Pharmaceuticals segment manufactures and sells ethical drugs, including NESP/ESPO, an ESA formulation; ALLELOCK, an antiallergic agent; Patanol antiallergic eye drops; CONIEL, a hypertension and angina pectoris; GRAN, a G-CSF product; DEPAKENE, an antiepileptic agent; NOURIAST, an antiparkinsonian agent; REGPARA, a calcium receptor agonist; Abstral, a treatment for managing cancer pain; Fentos, a transdermal product; ASACOL, an ulcerative colitis treatment; ONGLYZA for the treatment of type 2 diabetes; Romiplate, an idiopathic thrombocytopenic purpura and thrombopoietin receptor agonist; and POTELIGEO for relapsed CCR4-positive peripheral T-cell lymphoma, as well as Dovobet, a psoriasis vulgaris treatment; and G-Lasta for the treatment of chemotherapy induced febrile neutropenia. Its Bio-chemicals segment produces and sells amino acids, nucleotides vitamins, and sugars for use in pharmaceuticals, health foods, cosmetics, and other products. This segment also produces plant growth regulators; designs and installs plant facilities and equipment; manufactures active pharmaceutical ingredients, pharmaceutical intermediates, industrial raw materials, and health care products; sells fine chemicals; and is involved in mail-order sale of healthcare products. The company also engages in pharmaceuticals licensing, insurance, wholesale, and retail activities. Kyowa Hakko Kirin Co., Ltd. was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

7,424 Employees
Last Reported Date: 03/13/15
Founded in 1949

kyowa hakko kirin co ltd (4151) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kyowa hakko kirin co ltd (4151) Key Developments

Kyowa Hakko Kirin Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2015 and Full Year Ending December 31, 2015

Kyowa Hakko Kirin Co., Ltd. provided consolidated earnings guidance for the six months ended June 30, 2015 and full year ending December 31, 2015. For the six months, the company now expects net sales of JPY 178,800 million against previous guidance of JPY 172,000 million. Operating income expected to be JPY 22,400 million against previous guidance of JPY 16,500 million. In the consolidated results for the interim period, sales and operating income in the Pharmaceuticals business are higher than the initial plan. For the year, the company now expects net sales of JPY 360,000 million against previous guidance of JPY 354,000 million. Operating income expected to be JPY 47,000 million against previous guidance of JPY 41,500 million. Ordinary income expected to be JPY 41,000 million against previous guidance of JPY 34,000 million. Net income expected to be JPY 26,000 million against previous guidance of JPY 18,500 million. Net income per share expected to be JPY 47.51 against previous guidance of JPY 33.80. In addition, the share of loss of entities accounted for using the equity method and the income tax rate are expected to decline, influencing net income for the full year.

Astrazeneca Signs Commercialization Deal with Kyowa Hakko Kirin Co., Ltd. for Benralizumab

Astrazeneca has entered an agreement with Kyowa Hakko Kirin Co. Ltd. for an exclusive option to commercialize benralizumab for asthma and chronic obstructive pulmonary disease (COPD) in Japan. Benralizumab is a monoclonal antibody in Phase III development for the treatment of severe uncontrolled asthma and COPD. It targets the IL-5 receptor and depletes eosinophils, which play a key role in inflammatory respiratory disease. Under the terms of the agreement, AstraZeneca will pay Kyowa Hakko Kirin a $45 million up-front option fee and subsequent payments for regulatory filing, approval and commercial milestones, and sales royalties. Kyowa Hakko Kirin will continue to be responsible for the research and development of benralizumab in Japan. On exercising the option, AstraZeneca will be responsible for all sales and marketing in asthma and COPD in Japan. Kyowa Hakko Kirin will retain the rights to participate in certain commercial activities alongside AstraZeneca.

Kyowa Hakko Kirin Co., Ltd. to Report Q2, 2015 Results on Jul 31, 2015

Kyowa Hakko Kirin Co., Ltd. announced that they will report Q2, 2015 results on Jul 31, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4151:JP ¥2,018.00 JPY +39.00

4151 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Genmab A/S kr639.50 DKK +1.50
ImmunoGen Inc $18.15 USD +0.25
Insys Therapeutics Inc $45.04 USD +1.02
MorphoSys AG €73.57 EUR +1.37
Seattle Genetics Inc $47.74 USD +0.395
View Industry Companies

Industry Analysis


Industry Average

Valuation 4151 Industry Range
Price/Earnings 74.0x
Price/Sales 3.1x
Price/Book 1.7x
Price/Cash Flow 29.9x
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYOWA HAKKO KIRIN CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at